Off-topic for aiqbench

This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.

Huahai Pharma: Clinical Trial for New Indication of Subsidiary's HB0056 Injection Approved

36KrNovember 2, 20261 min read

36Kr learned that Huahai Pharma announced that its subsidiaries Shanghai Huaaotai Biopharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd. recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the addition of a chronic obstructive pulmonary disease indication to the HB0056 injection project.

Read the full article at 36Kr

Read at 36Kr ↗Ask about this article